Chemoinformaics analysis of (+ )-erythrinine
| Molecular Weight | 313.353 | nRot | 1 |
| Heavy Atom Molecular Weight | 294.201 | nRig | 24 |
| Exact Molecular Weight | 313.131 | nRing | 5 |
| Solubility: LogS | -1.715 | nHRing | 3 |
| Solubility: LogP | 0.987 | No. of Aliphatic Rings | 4 |
| Acid Count | 0 | No. of Aromatic Rings | 1 |
| Base Count | 1 | No. of Aliphatic Carbocycles Rings | 1 |
| Atoms Count | 42 | No. of Aliphatic Hetero Cycles | 3 |
| No. of Heavy Atom | 23 | No. of Aromatic Carbocycles | 1 |
| nHetero | 5 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 19 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 18 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 1 | No. of Arom Atom | 6 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 6 |
| nHA | 5 | APOL | 47.0371 |
| nHD | 1 | BPOL | 25.9789 |
| QED | 0.858 |
| Synth | 4.989 |
| Natural Product Likeliness | 2.893 |
| NR-PPAR-gamma | 0.005 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.162 |
| Pgp-sub | 0.879 |
| HIA | 0.005 |
| CACO-2 | -4.742 |
| MDCK | 0.0000247 |
| BBB | 0.994 |
| PPB | 0.668981 |
| VDSS | 3.759 |
| FU | 0.205682 |
| CYP1A2-inh | 0.073 |
| CYP1A2-sub | 0.478 |
| CYP2c19-inh | 0.086 |
| CYP2c19-sub | 0.919 |
| CYP2c9-inh | 0.22 |
| CYP2c9-sub | 0.744 |
| CYP2d6-inh | 0.373 |
| CYP2d6-sub | 0.284 |
| CYP3a4-inh | 0.897 |
| CYP3a4-sub | 0.939 |
| CL | 15.643 |
| T12 | 0.425 |
| hERG | 0.298 |
| Ames | 0.437 |
| ROA | 0.245 |
| SkinSen | 0.549 |
| Carcinogencity | 0.837 |
| EI | 0.009 |
| Respiratory | 0.822 |
| NR-Aromatase | 0.039 |
| Antiviral | Yes |
| Prediction | 0.698794 |